Avita Medical Inc

Financials

Flusso di cassa derivante dalle attività operative -25.9 M-19.09 M-38.01 M-48.94 M-31.2 M -31.2 M Flussi di cassa derivanti dalle attività di investimento -1.17 M-19.33 M1.61 M37.36 M12.45 M 12.45 M Liquidità derivante dalle attività di finanziamento 64.05 M900 K40.37 M3.51 M14.94 M 14.94 M Liquidità libera -27.07 M-19.61 M-39.46 M-58.27 M-32.93 M -32.3 M

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa and Australia.

RCEL

Financials

Avita Medical Inc

Notizie

AVITA Medical: Why The BARDA Rally Changes Nothing (NASDAQ:RCEL)

AVITA Medical ottiene contratto BARDA da 25,5 mln $ per emergenze ustioni

Avita Medical alla conferenza TD Cowen: crescita e focus strategico

Avita Medical at TD Cowen Conference: Growth and Strategic Focus

Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade

Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know

AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript

AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript

Avita Medical Q4 2025: crescita annuale dell’11% con espansione 12-19% prevista per il 2026

Avita Medical Q4 2025 slides: 11% annual growth with 12-19% expansion targeted for 2026

Gli EPS di Avita Medical sono risultati in linea con le aspettative, il fatturato supera le previsioni

Avita Medical Stock: Skin Regeneration Platform Is Set Up For A Turnaround (NASDAQ:RCEL)